Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for PRTA

Stock NameProthena Corporation plc
TickerPRTA(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINIE00B91XRN20

Show aggregate PRTA holdings

News associated with PRTA

Prothena Corporation plc (NASDAQ:PRTA) Receives $30.25 Average PT from Brokerages
Shares of Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) have received a consensus rating of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on […] - 2025-08-19 04:26:55
Chicago Partners Investment Group LLC Buys 3,315 Shares of Prothena Corporation plc (NASDAQ:PRTA)
Chicago Partners Investment Group LLC grew its holdings in Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 29.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,512 shares of the biotechnology company’s stock after buying an additional 3,315 shares during the period. Chicago […] - 2025-08-13 05:18:49
TD Asset Management Inc Reduces Stock Position in Prothena Corporation plc (NASDAQ:PRTA)
TD Asset Management Inc cut its stake in Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 3.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,694 shares of the biotechnology company’s stock after selling 2,000 shares during the period. TD Asset Management […] - 2025-08-05 04:37:17
Brokerages Set Prothena Corporation plc (NASDAQ:PRTA) Target Price at $31.50
Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) has earned an average recommendation of “Hold” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have issued a buy recommendation on the company. […] - 2025-07-25 05:12:48
Alps Advisors Inc. Has $470,000 Stake in Prothena Corporation plc (NASDAQ:PRTA)
Alps Advisors Inc. trimmed its position in shares of Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 12.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,956 shares of the biotechnology company’s stock after selling 5,554 shares during the period. Alps Advisors Inc. […] - 2025-07-15 06:59:50
Cambridge Investment Research Advisors Inc. Acquires New Stake in Prothena Corporation plc (NASDAQ:PRTA)
Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Prothena Corporation plc (NASDAQ:PRTA – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,164 shares of the biotechnology company’s stock, valued at approximately $126,000. A number of […] - 2025-07-15 04:17:25
SG Americas Securities LLC Raises Stock Holdings in Prothena Corporation plc (NASDAQ:PRTA)
SG Americas Securities LLC increased its position in Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 92.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,559 shares of the biotechnology company’s stock after acquiring an additional 34,947 shares during the period. SG […] - 2025-06-19 04:30:54
Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Two Sigma Investments LP
Two Sigma Investments LP increased its stake in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 265.4% during the 4th quarter, Holdings Channel reports. The fund owned 38,394 shares of the biotechnology company’s stock after purchasing an additional 27,887 shares during the quarter. Two Sigma Investments LP’s holdings in Prothena were worth $532,000 as of […] - 2025-06-09 04:30:53
Hennion & Walsh Asset Management Inc. Buys 25,353 Shares of Prothena Co. plc (NASDAQ:PRTA)
Hennion & Walsh Asset Management Inc. lifted its holdings in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 48.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 77,637 shares of the biotechnology company’s stock after purchasing an additional 25,353 shares during the period. Hennion & Walsh Asset […] - 2025-06-08 05:53:06
Bank of America Corp DE Acquires 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA)
Bank of America Corp DE increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 45.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 119,007 shares of the biotechnology company’s stock after buying an additional 36,944 shares […] - 2025-06-05 05:14:52
Prothena (NASDAQ:PRTA) Earns “Underperform” Rating from Bank of America
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating restated by stock analysts at Bank of America in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. A number of other analysts have also recently weighed in on PRTA. Cantor Fitzgerald cut shares of Prothena from an “overweight” rating to […] - 2025-05-30 05:06:52
Bank of America Reaffirms Underperform Rating for Prothena (NASDAQ:PRTA)
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating restated by research analysts at Bank of America in a note issued to investors on Wednesday, MarketBeat.com reports. A number of other equities analysts have also issued reports on PRTA. Cantor Fitzgerald lowered shares of Prothena from an “overweight” rating to a “neutral” rating […] - 2025-05-30 05:06:52
Prothena (NASDAQ:PRTA) Receives “Underperform” Rating from Bank of America
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating reiterated by Bank of America in a research note issued to investors on Wednesday, Marketbeat Ratings reports. PRTA has been the topic of several other reports. Cantor Fitzgerald cut shares of Prothena from an “overweight” rating to a “neutral” rating in a report on […] - 2025-05-30 05:06:52
Prothena (NASDAQ:PRTA) Given Underperform Rating at Bank of America
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating reiterated by stock analysts at Bank of America in a note issued to investors on Wednesday, MarketBeat.com reports. PRTA has been the topic of a number of other reports. Wall Street Zen upgraded Prothena from a “sell” rating to a “hold” rating in a […] - 2025-05-30 05:06:52
Prothena (NASDAQ:PRTA) Downgraded by Jefferies Financial Group to “Hold”
Prothena (NASDAQ:PRTA – Get Free Report) was downgraded by stock analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a report issued on Tuesday, Marketbeat Ratings reports. They presently have a $6.00 price target on the biotechnology company’s stock. Jefferies Financial Group’s target price indicates a potential upside of 30.43% […] - 2025-05-29 03:02:58
JMP Securities Lowers Prothena (NASDAQ:PRTA) Price Target to $29.00
Prothena (NASDAQ:PRTA – Get Free Report) had its target price cut by JMP Securities from $78.00 to $29.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. A number of other equities analysts have also commented on the company. Wall Street Zen raised Prothena […] - 2025-05-29 03:02:57
Prothena (NASDAQ:PRTA) Rating Lowered to Neutral at Cantor Fitzgerald
Prothena (NASDAQ:PRTA – Get Free Report) was downgraded by research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, MarketBeat reports. Several other equities research analysts have also recently issued reports on PRTA. Royal Bank of Canada lowered their price objective […] - 2025-05-29 03:02:53
HC Wainwright Cuts Prothena (NASDAQ:PRTA) Price Target to $14.00
Prothena (NASDAQ:PRTA – Get Free Report) had its price objective decreased by analysts at HC Wainwright from $30.00 to $14.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 204.35% from the company’s current […] - 2025-05-29 02:15:04
Piper Sandler Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price
Prothena (NASDAQ:PRTA – Free Report) had its target price decreased by Piper Sandler from $110.00 to $81.00 in a research report released on Tuesday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the biotechnology company’s stock. A number of other research firms have also commented on PRTA. Oppenheimer lowered Prothena from an “outperform” […] - 2025-05-28 04:46:49
Chardan Capital Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price
Prothena (NASDAQ:PRTA – Free Report) had its price objective lowered by Chardan Capital from $40.00 to $18.00 in a research note released on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. A number of other equities research analysts have also recently commented on the stock. Oppenheimer raised their […] - 2025-05-28 02:52:54
Traders Purchase High Volume of Put Options on Prothena (NASDAQ:PRTA)
Prothena Co. plc (NASDAQ:PRTA – Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock traders bought 8,185 put options on the company. This is an increase of approximately 1,210% compared to the average volume of 625 put options. Prothena Price Performance Shares of PRTA stock opened at $4.58 on Wednesday. […] - 2025-05-28 02:06:46
Balyasny Asset Management L.P. Makes New $527,000 Investment in Prothena Co. plc (NASDAQ:PRTA)
Balyasny Asset Management L.P. acquired a new position in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 38,021 shares of the biotechnology company’s stock, valued at approximately $527,000. Balyasny Asset Management L.P. […] - 2025-05-16 05:52:58
Raymond James Financial Inc. Takes Position in Prothena Co. plc (NASDAQ:PRTA)
Raymond James Financial Inc. purchased a new stake in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 13,111 shares of the biotechnology company’s stock, valued at approximately $182,000. Several other institutional investors and […] - 2025-05-13 04:18:47
Prothena (NASDAQ:PRTA) Price Target Lowered to $30.00 at HC Wainwright
Prothena (NASDAQ:PRTA – Free Report) had its price objective reduced by HC Wainwright from $48.00 to $30.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other brokerages have also weighed in on PRTA. Piper Sandler boosted their price objective on shares […] - 2025-05-12 02:44:45
JMP Securities Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price
Prothena (NASDAQ:PRTA – Free Report) had its target price reduced by JMP Securities from $80.00 to $78.00 in a report published on Friday morning,Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock. A number of other equities research analysts also recently issued reports on the stock. Cantor Fitzgerald reiterated an […] - 2025-05-12 02:44:45
Hsbc Holdings PLC Grows Holdings in Prothena Co. plc (NASDAQ:PRTA)
Hsbc Holdings PLC increased its stake in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 60.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 24,179 shares of the biotechnology company’s stock after purchasing an additional 9,101 shares during the period. Hsbc Holdings PLC’s holdings […] - 2025-05-09 05:41:02
Renaissance Technologies LLC Acquires 19,100 Shares of Prothena Co. plc (NASDAQ:PRTA)
Renaissance Technologies LLC increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 10.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,900 shares of the biotechnology company’s stock after purchasing an additional 19,100 shares during the period. […] - 2025-04-25 05:54:49
Corebridge Financial Inc. Trims Position in Prothena Co. plc (NASDAQ:PRTA)
Corebridge Financial Inc. trimmed its position in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 7.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,140 shares of the biotechnology company’s stock after selling 1,596 shares during the quarter. […] - 2025-04-11 05:40:59
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Rating of “Moderate Buy” by Analysts
Prothena Co. plc (NASDAQ:PRTA – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among […] - 2025-04-11 04:32:50
KLP Kapitalforvaltning AS Acquires New Shares in Prothena Co. plc (NASDAQ:PRTA)
KLP Kapitalforvaltning AS acquired a new position in Prothena Co. plc (NASDAQ:PRTA – Free Report) in the fourth quarter, HoldingsChannel reports. The fund acquired 12,900 shares of the biotechnology company’s stock, valued at approximately $179,000. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PRTA. Orion Portfolio […] - 2025-04-09 04:28:47

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) PRTA holdings

DateNumber of PRTA Shares HeldBase Market Value of PRTA SharesLocal Market Value of PRTA SharesChange in PRTA Shares HeldChange in PRTA Base ValueCurrent Price per PRTA Share HeldPrevious Price per PRTA Share Held
2025-11-12 (Wednesday)35,381USD 383,884USD 383,884
2025-11-11 (Tuesday)35,289USD 369,829PRTA holding decreased by -1764USD 369,8290USD -1,764 USD 10.48 USD 10.53
2025-11-10 (Monday)35,289PRTA holding increased by 91USD 371,593PRTA holding decreased by -98USD 371,59391USD -98 USD 10.53 USD 10.56
2025-11-07 (Friday)35,198USD 371,691PRTA holding increased by 16895USD 371,6910USD 16,895 USD 10.56 USD 10.08
2025-11-06 (Thursday)35,198PRTA holding increased by 91USD 354,796PRTA holding decreased by -5753USD 354,79691USD -5,753 USD 10.08 USD 10.27
2025-11-05 (Wednesday)35,107USD 360,549PRTA holding increased by 351USD 360,5490USD 351 USD 10.27 USD 10.26
2025-11-04 (Tuesday)35,107PRTA holding increased by 92USD 360,198PRTA holding decreased by -8860USD 360,19892USD -8,860 USD 10.26 USD 10.54
2025-11-03 (Monday)35,015USD 369,058PRTA holding decreased by -7353USD 369,0580USD -7,353 USD 10.54 USD 10.75
2025-10-31 (Friday)35,015USD 376,411PRTA holding increased by 9454USD 376,4110USD 9,454 USD 10.75 USD 10.48
2025-10-30 (Thursday)35,015PRTA holding increased by 460USD 366,957PRTA holding decreased by -1054USD 366,957460USD -1,054 USD 10.48 USD 10.65
2025-10-29 (Wednesday)34,555PRTA holding increased by 184USD 368,011PRTA holding increased by 5741USD 368,011184USD 5,741 USD 10.65 USD 10.54
2025-10-28 (Tuesday)34,371USD 362,270PRTA holding increased by 5843USD 362,2700USD 5,843 USD 10.54 USD 10.37
2025-10-27 (Monday)34,371USD 356,427PRTA holding increased by 18904USD 356,4270USD 18,904 USD 10.37 USD 9.81999
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PRTA by Blackrock for IE00BYXG2H39

Show aggregate share trades of PRTA

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY9111.09010.465 10.527USD 958 10.90
2025-11-06BUY9110.49010.015 10.063USD 916 10.91
2025-11-04BUY9210.56010.160 10.200USD 938 10.91
2025-10-30BUY46010.81510.345 10.392USD 4,780 10.92
2025-10-29BUY18410.65010.795 10.781USD 1,984 10.92
2025-10-22SELL-3649.88010.350 10.303USD -3,750 10.94 Profit of 233 on sale
2025-10-20BUY18210.37010.550 10.532USD 1,917 10.95
2025-10-17BUY4549.92010.230 10.199USD 4,630 10.96
2025-10-15BUY72010.66010.720 10.714USD 7,714 10.96
2025-10-03BUY6449.92010.160 10.136USD 6,528 10.97
2025-10-02BUY929.99010.220 10.197USD 938 10.97
2025-09-30BUY1849.7609.850 9.841USD 1,811 10.99
2025-09-26BUY1849.4109.460 9.455USD 1,740 11.00
2025-09-25BUY1849.3609.560 9.540USD 1,755 11.01
2025-09-18BUY948.1808.350 8.333USD 783 11.04
2025-09-17BUY2828.0608.385 8.353USD 2,355 11.06
2025-08-20SELL-3688.5208.595 8.588USD -3,160 11.12 Profit of 932 on sale
2025-07-30BUY3646.8807.330 7.285USD 2,652 11.25
2025-07-17SELL-1846.4706.600 6.587USD -1,212 11.53 Profit of 909 on sale
2025-07-11SELL-7446.4006.520 6.508USD -4,842 11.67 Profit of 3,839 on sale
2025-07-07BUY2796.2906.470 6.452USD 1,800 11.81
2025-07-02BUY5,1156.3206.585 6.559USD 33,547 11.89
2025-06-11BUY1885.1005.390 5.361USD 1,008 12.28
2025-06-10BUY1885.2605.450 5.431USD 1,021 12.33
2025-06-04SELL-944.8804.880 4.880USD -459 12.55 Profit of 721 on sale
2025-04-23BUY929.59010.070 10.022USD 922 14.18
2025-04-10SELL-7369.69010.155 10.108USD -7,440 14.65 Profit of 3,341 on sale
2025-04-08SELL-9110.48011.500 11.398USD -1,037 14.75 Profit of 305 on sale
2025-04-07SELL-9110.84011.280 11.236USD -1,022 14.79 Profit of 324 on sale
2025-04-04SELL-46010.86011.370 11.319USD -5,207 14.84 Profit of 1,619 on sale
2025-04-01BUY37611.74012.448 12.377USD 4,654 14.91
2025-03-31SELL-27612.37512.705 12.672USD -3,497 14.94 Profit of 626 on sale
2025-03-21BUY1,75712.97012.990 12.988USD 22,820 15.09
2025-03-14SELL-1,39213.74014.340 14.280USD -19,878 15.22 Profit of 1,305 on sale
2025-03-07SELL-17215.27015.626 15.590USD -2,682 15.29 Loss of -52 on sale
2025-03-04SELL-8615.06015.510 15.465USD -1,330 15.30 Loss of -14 on sale
2025-02-25BUY17414.63015.390 15.314USD 2,665 15.33
2025-02-19SELL-8614.98015.075 15.065USD -1,296 15.34 Profit of 24 on sale
2025-02-13BUY25813.89013.920 13.917USD 3,591 15.44
2025-02-12BUY8613.82013.920 13.910USD 1,196 15.48
2025-02-11BUY34413.79014.110 14.078USD 4,843 15.51
2024-12-30SELL-2,75714.88015.250 15.213USD -41,942 15.85 Profit of 1,743 on sale
2024-11-18SELL-1,38313.51014.155 14.090USD -19,487 17.07 Profit of 4,115 on sale
2024-11-08SELL-9217.70017.920 17.898USD -1,647 17.00 Loss of -83 on sale
2024-10-21SELL-9316.50017.030 16.977USD -1,579 0.00 Loss of -1,579 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PRTA

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19108,3170182,19359.5%
2025-09-1865,5460159,08441.2%
2025-09-1788,134851183,39448.1%
2025-09-1656,7370121,37146.7%
2025-09-15120,935188321,91237.6%
2025-09-1279,6070177,44344.9%
2025-09-1195,3740287,70133.2%
2025-09-1056,2860176,09032.0%
2025-09-09102,797200405,12325.4%
2025-09-0880,7590241,85433.4%
2025-09-0579,4740527,64115.1%
2025-09-04129,8930344,75837.7%
2025-09-03101,0660507,34919.9%
2025-09-0279,7730480,12516.6%
2025-08-29137,2870380,23736.1%
2025-08-28251,36427,779681,66236.9%
2025-08-2782,656202371,97522.2%
2025-08-2663,2193,211241,51626.2%
2025-08-2587,2910233,97237.3%
2025-08-2276,1540487,31115.6%
2025-08-2182,6000393,33521.0%
2025-08-2056,4090225,10425.1%
2025-08-1989,0140357,09324.9%
2025-08-18107,5970529,22520.3%
2025-08-1570,4150445,98115.8%
2025-08-1452,5920203,47725.8%
2025-08-1392,6680629,88714.7%
2025-08-12111,52713,821344,14432.4%
2025-08-11110,1990376,93329.2%
2025-08-08155,2750374,24441.5%
2025-08-07120,9430251,06948.2%
2025-08-06339,64917,3561,549,64221.9%
2025-08-05251,73419,116638,38839.4%
2025-08-04113,26564364,14431.1%
2025-08-01130,04479324,25340.1%
2025-07-31132,258534337,23139.2%
2025-07-30179,5896,037653,05927.5%
2025-07-29148,926111328,23245.4%
2025-07-28110,0970308,96535.6%
2025-07-25105,6560379,13427.9%
2025-07-2483,1560295,01028.2%
2025-07-23106,1090341,01231.1%
2025-07-2273,0320249,70129.2%
2025-07-21119,0400249,41847.7%
2025-07-18124,7040299,01841.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.